Clinical Trial Update: Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS [Phase 1, Phase 2]

View source ↗

Summary

This trial update reports on the safety, tolerability, and preliminary efficacy of monthly long-acting glatiramer acetate depot injections (80 mg or 40 mg) in a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Glatiramer acetate depot (glatiramer acetate)

Snippet

Sponsor: Mapi Pharma Ltd. | Conditions: Multiple Sclerosis | Phase 1, Phase 2 | Status: COMPLETED